Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first of several phase 3 drug trials.The jump in share price propelled the stock into positive territory -- it was up nearly 9% year to date as of this writing, and up about 12% over the past 12 months.Let's look at why this news could be a game-changer for Eli Lilly and its stock.Continue reading
Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first of several phase 3 drug trials.
The jump in share price propelled the stock into positive territory -- it was up nearly 9% year to date as of this writing, and up about 12% over the past 12 months.
Let's look at why this news could be a game-changer for Eli Lilly and its stock.